<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568241</url>
  </required_header>
  <id_info>
    <org_study_id>2015-10</org_study_id>
    <nct_id>NCT02568241</nct_id>
  </id_info>
  <brief_title>Interferon-α After DLI for the Prevention of Relapse</brief_title>
  <acronym>IDPR-HSCT</acronym>
  <official_title>Interferon α After Prophylactic Donor Lymphocyte Infusion for the Relapse Prevention After Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to evaluate the efficacy of interferon α after prophylactic donor lymphocyte
      infusion (DLI) among high-risk acute leukemia patients undergone unmanipulated blood and
      marrow transplantation. Hematopoietic stem cell transplantation (HSCT) is an effective
      treatment option for high-risk acute leukemia (AL). However, post-transplant relapse can
      occur in some patients, and the prognosis of these patients is usually very poor.Prophylactic
      DLI can decrease the risk of relapse of high-risk AL patients. Interferon α-2b exerts a
      relatively strong immunomodulatory effect. It can kill AL cells by regulating T-cell and/or
      natural killer cell functions.Consequently, interferon α-2b may have potential value for
      high-risk AL patients after transplantation. The study hypothesis: Using interferon α-2b
      after prophylactic DLI following hematopoietic stem cell transplantation in patients with
      high-risk AL can further reduce relapse rate and improve leukemia-free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High risk acute leukemia patients (except t(9;22)(q34; q11) cytogenetic abnormalities.)
      received interferon α-2b after prophylactic DLI at day 30-60 after unmanipulated blood and
      marrow transplantation. The end points were safety, leukemia-free survival, and immunologic
      response. Following time is 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leukemia free survival</measure>
    <time_frame>Participants will be followed for an expected average of 3 years</time_frame>
    <description>Number of participants survived without leukemia at three years</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>interferon Alfa-2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-risk acute leukemia patients after hematopoietic stem cell transplantation receive interferon Alfa-2b after prophylactic DLI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interferon Alfa-2b</intervention_name>
    <description>High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>interferon Alfa-2b</arm_group_label>
    <other_name>INF α-2b</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who had high-risk acute leukemia after hematopoietic stem cell
             transplantation

        Exclusion Criteria:

          -  Patients with t(9;22)(q34; q11) cytogenetic abnormalities;active graft-versus-host
             disease; active infection; organ failure, or relapse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Jun HUANG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Institute of Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Dong MO, MD</last_name>
    <phone>86-10-88326001</phone>
    <email>mxd453@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Institute of Hematology,Beijing</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Dong Mo</last_name>
      <email>mxd453@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiao-Jun Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Interferon Alfa-2b</keyword>
  <keyword>Relapse</keyword>
  <keyword>Donor lymphocyte infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

